drugs for infants and children: call for reform

AIDS Treatment News Drugs for Infants and Children: Call for Reform John S. James
November 4, 1994

AIDS TREATMENT NEWS Issue #210, November 4, 1994 Infants and children with life-threatening diseases face a shocking lack of drugs tested for safety in children -- and tested for the stability of the improvised formulations doctors are often forced to use. At the same time, unnecessary efficacy testing in children -- for example, testing in children of biologically inappropriate ages -- delays treatment availability, and creates obstacles to the testing which is necessary. Arthur J. Ammann, M.D., Research Director of the Pediatric AIDS Foundation, and a member of the National Task Force on AIDS Drug Development, analyzed these problems in a presentation to the Task Force on October 28. He made 14 recommendations for improvement, directed toward the approval of drugs for life-threatening conditions simultaneously for both children and adults. We cannot summarize the 10-page testimony of Dr. Ammann -- an expert in drug development who was formerly a leading researcher at Genentech, Inc. The bottom line is that this problem is far more serious than generally realized -- and far more correctable. The kinds of re-thinking proposed would improve drug development generally, for adults as well as for children. For more information, contact Dr. Ammann at the Pediatric AIDS Foundation, 81 Digital Drive, Novato, CA 94949, 415/883- 1796.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 ARIZONA: Routine Skin Testing Available Again at Tuberculosis Clinic Starting May 20 NORTH DAKOTA: Officials: 26 Tuberculosis Cases from Grand Forks Outbreak AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common CANADA: Nunavut Uses Comic Book to Do Sex Education NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing UNITED STATES: Hepatitis C Testing for People Born Between 1945 and 1965 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs NORTH KOREA: North Korea Sees Surge of Drug-Resistant Tuberculosis Experimental Gilead drug effective in early-stage leukemia trial Public Meeting on HIV Patient-Focused Drug Development and HIV Cure Research: June 14, 2013 India's Largest Generic Drugmaker Ranbaxy Pays $500 Million to Settle Systemic Generic Drug Manufacturing Fraud Antiretroviral regimen associated with less virological failure among HIV-infected children AHF Shareholder Advocates Challenge Gilead on Drug Pricing at AGM NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative 2012 US medicine sales show shifts by drug type KENYA: AHF, KANCO Organize NO RETREAT ON AIDS March to Call for More Global HIV/AIDS Funding
Copyright © 1994 -AIDS Treatment News, Publisher. All rights reserved to AIDS Treatment News (ATN), Email AIDS Treatment News . Information in this article was accurate in November 4, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.